Management of Hepatitis C Infection
Summary
- Genotype 1 Patients
- AASLD/IDSA guidelines recommend DAA-based regimens for genotype 1 HCV–infected patients according to subgenotype, presence of baseline NS5A resistance associated mutations, and cirrhosis status (Table 29) (Table 30) (Management Guidelines)[AASLD-IDSA HCV]
- EASL guidelines also recommend DAA-based regimens for treatment-naive and interferon/ribavirin-experienced patients with genotype 1 HCV infection according to subgenotype and cirrhosis status (Table 31) (Management Guidelines)[EASL HCV]
- AASLD/IDSA guidelines recommend glecaprevir/pibrentasvir and sofosbuvir/velpatasvir as the preferred options for genotype 2 HCV–infected patients (Management Guidelines)[AASLD-IDSA HCV]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment